Project Grant R01HL174774

Award Date 6/15/24
Completion Date 5/31/28
Dollars Obligated $663K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $243,000 in funding to the University of Cincinnati to develop innovative RNA biodevices that integrate CRISPR and ADAR gene-editing technologies. The goal is to enhance the efficiency and specificity of converting fibroblasts into cardiac cells for in vivo reprogramming strategies to address excessive fibrosis and heart failure following...
The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham (UAB) a $561,392 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of RNA methylation in cardiac fibrosis and heart failure progression. The key objectives of this 4-year research project are to: 1) Investigate the direct link between the RNA methyltransferase METTL3 activation and cardiac fibrosis progression using a fibroblast-specific...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $106,201 to the University of North Carolina at Chapel Hill (UNC-CH) to support research on post-transcriptional mechanisms regulating direct cardiac reprogramming. The project aims to characterize the mechanisms by which the innovative TBX5+siYBX1 cocktail can reprogram cardiac fibroblasts into induced cardiomyocyte-like cells, as well...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $100,480 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Texas Southwestern Medical Center. The grant, titled "RBPMS, A NOVEL RNA SPLICING REGULATOR OF CARDIAC FUNCTION AND DISEASE", will support research to characterize how the RNA-binding protein RBPMS regulates cardiomyocyte contraction and cardiac function through modulating alternative RNA splicing. The project...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $361,083 to Childrens Hospital Medical Center in Cincinnati, Ohio to investigate how the acetylation of the transcriptional regulator YAP affects its subcellular localization and role in cardiac regeneration following myocardial infarction. The research aims to elucidate how metabolic stresses regulate YAP acetylation through...
The federal Project Grant award R01HL178582, totaling $496,367.00 and issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at Duke University to develop novel approaches for cardiac reprogramming. The key objectives are to: 1) investigate the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, 2) determine if targeting this repressor complex can improve the efficacy of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is supporting research to investigate the role of mitochondrial signaling between cardiomyocytes and cardiac fibroblasts in the pathogenesis of cardiac fibrosis. The $639,621 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will fund a 4-year research project to test the hypothesis that intact...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $721,826 to the Childrens Hospital Medical Center in Cincinnati, Ohio to conduct research on the transcription factor MEOX2 and its role in regulating alveolar fibroblast function. The research aims to elucidate the molecular mechanisms by which MEOX2 regulates the differentiation and function of alveolar matrix and...
The federal Project Grant award R01HL174940, totaling $785,198, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research grant program (CFDA 93.837). The grant supports research to investigate the role of chaperone-mediated autophagy (CMA) in regulating the function and phenotypic transitions of fibroblasts and myofibroblasts during cardiac tissue repair and remodeling following myocardial infarction. The project aims to study how CMA...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to uncover effective strategies for mitigating the detrimental effects of cardiac fibrosis in diseases like dilated cardiomyopathy (DCM). The $159,512 award will fund the validation and description of the anti-fibrotic mechanisms of two drug compounds, CGS15943 and AM404, in a mouse model of LMNA-related DCM. The research...

ROLE OF RBP IN PROGRAMMING AND REPROGRAMMING OF CARDIAC FIBROBLASTS - CARDIAC FIBROBLASTS (CFS) ARE THE MAJOR CARDIAC CELL TYPE RESPONSIBLE FOR PRODUCING EXTRACELLULAR MATRIX (ECM) PROTEINS, FORMING A STRUCTURAL SCAFFOLD CRUCIAL FOR SUPPORTING CARDIAC TISSUE DURING DEVELOPMENT AND HOMEOSTASIS. CFS ARE ALSO KNOWN FOR THEIR HIGH PLASTICITY, ENABLING THEM TO SWIFTLY RESPOND TO INJURIES AND PATHOLOGICAL CONDITIONS. UNDER SUCH CIRCUMSTANCES, CFS ARE RAPIDLY ACTIVATED AND BECOME TRANSDIFFERENTIATED INTO MYOFIBROBLASTS THAT PRODUCE AND SECRETE AN EXCESSIVE AMOUNT OF ECM COMPONENTS, ULTIMATELY LEADING TO FIBROTIC SCARRING THAT DISRUPTS TISSUE COMPLIANCE AND ACCELERATES THE PROGRESSION TOWARD HEART FAILURE. THE TRANSFORMATION OF CFS INTO MYOFIBROBLASTS REQUIRES WHOLESALE PROGRAMMING OF THE CF TRANSCRIPTOME. YET, IN ADDITION TO TRANSCRIPTIONAL REGULATION, POST-TRANSCRIPTIONAL REGULATION BY RNA-BINDING PROTEINS (RBPS) HAS EMERGED AS A CRITICAL REGULATORY LAYER FOR CONTROLLING GENE EXPRESSION. RBPS ACTIVELY REGULATE EVERY STEP OF MRNA LIFE CYCLE, INCLUDING SPLICING, STABILITY, AND TRANSLATION. IN OUR PRELIMINARY STUDIES, WE FOUND THAT ONE OF RBPS, YBX1, WAS SIGNIFICANTLY UPREGULATED DURING CF TO MYOFIBROBLAST CONVERSION AND FURTHER DISCOVERED A POTENTIALLY IMPORTANT ROLE OF THIS RBP IN MYOFIBROBLAST FORMATION. SPECIFICALLY, WE FOUND THAT TCF21:MERCREMER MEDIATED ABLATION OF YBX1 INHIBITS THE TRANSFORMATION OF CFS INTO MYOFIBROBLASTS AND REDUCES CARDIAC FIBROSIS. WHILE THE CONVERSION CFS TO MYOFIBROBLASTS IS INHERENTLY PATHOLOGICAL, THE EXTENSIVE POOL AND PLASTICITY OF RESIDENT CFS HAS BEEN RECENTLY HARNESSED FOR CARDIAC REGENERATION WHEREBY CFS ARE REPROGRAMMED INTO INDUCED CARDIOMYOCYTES (ICMS) BY LOCAL DELIVERY OF THREE CARDIAC TRANSCRIPTION FACTORS (TFS) - GATA4, MEF2C, TBX5 (ABBREVIATED AS GMT). BUILDING UPON OUR INTRIGUING FINDING THAT DEPLETION OF YBX1 ATTENUATES CF TO MYOFIBROBLAST CONVERSION AND REDUCES CARDIAC FIBROSIS, WE POSED THE QUESTION WHETHER YBX1 ABLATION ENHANCES GMT-MEDIATED ICM REPROGRAMMING. INDEED, OUR PRELIMINARY STUDY INDICATES THAT, COMPARED TO MGT-MEDIATED ICM REPROGRAMMING, DELIVERY OF GMT WITH YBX1 DEPLETION ENHANCES ICM INDUCTION, FURTHER ATTENUATING CARDIAC FIBROSIS AND IMPROVES HEART FUNCTION FOLLOWING MI. COMBINING THESE TWO LINES OF INVESTIGATION AND THE CORRESPONDING PRELIMINARY DATA, IN THIS PROPOSAL WE WILL LEVERAGE OUR SERIES OF UNIQUE TOOLS, REAGENTS, AND ANIMAL MODELS TO ADDRESS OUR HYPOTHESIS THAT YBX1 ACTIVITY EXERTS A SIGNIFICANT INFLUENCE ON THE FATE SWITCH INVOLVING CFS, SPECIFICALLY THE TRANSFORMATION OF CFS INTO MYOFIBROBLASTS AND THE REPROGRAMMING OF CFS INTO ICMS, WHICH CAN BE LEVERAGED FOR REDUCING FIBROTIC SCARRING AND REGENERATING LOST MYOCARDIUM AFTER MI.

Posted 6/10/24, 12:00 AM